nodes	percent_of_prediction	percent_of_DWPC	metapath
Dihydroergotamine—migraine—Prednisone—prostate cancer	0.411	1	CpDpCtD
Dihydroergotamine—CYP3A4—prostate cancer	0.108	1	CbGaD
Dihydroergotamine—CYP3A4—Estradiol valerate/Dienogest—prostate cancer	0.0323	0.112	CbGbCtD
Dihydroergotamine—ABCB1—Estramustine—prostate cancer	0.0263	0.0915	CbGbCtD
Dihydroergotamine—ABCB1—Cabazitaxel—prostate cancer	0.0173	0.0603	CbGbCtD
Dihydroergotamine—CYP3A4—Bicalutamide—prostate cancer	0.017	0.0589	CbGbCtD
Dihydroergotamine—ABCB1—Estrone—prostate cancer	0.017	0.0589	CbGbCtD
Dihydroergotamine—CYP3A4—Estramustine—prostate cancer	0.0158	0.0548	CbGbCtD
Dihydroergotamine—ABCB1—Ethinyl Estradiol—prostate cancer	0.0151	0.0525	CbGbCtD
Dihydroergotamine—CYP3A4—Abiraterone—prostate cancer	0.0141	0.0488	CbGbCtD
Dihydroergotamine—CYP3A4—Flutamide—prostate cancer	0.0141	0.0488	CbGbCtD
Dihydroergotamine—ABCB1—Conjugated Estrogens—prostate cancer	0.0111	0.0386	CbGbCtD
Dihydroergotamine—CYP3A4—Cabazitaxel—prostate cancer	0.0104	0.0361	CbGbCtD
Dihydroergotamine—CYP3A4—Estrone—prostate cancer	0.0102	0.0353	CbGbCtD
Dihydroergotamine—ABCB1—Mitoxantrone—prostate cancer	0.0101	0.0351	CbGbCtD
Dihydroergotamine—ABCB1—Estradiol—prostate cancer	0.00974	0.0339	CbGbCtD
Dihydroergotamine—CYP3A4—Ethinyl Estradiol—prostate cancer	0.00905	0.0315	CbGbCtD
Dihydroergotamine—ABCB1—Prednisone—prostate cancer	0.00837	0.0291	CbGbCtD
Dihydroergotamine—CYP3A4—Conjugated Estrogens—prostate cancer	0.00665	0.0231	CbGbCtD
Dihydroergotamine—ABCB1—Etoposide—prostate cancer	0.00636	0.0221	CbGbCtD
Dihydroergotamine—CYP3A4—Mitoxantrone—prostate cancer	0.00604	0.021	CbGbCtD
Dihydroergotamine—CYP3A4—Estradiol—prostate cancer	0.00583	0.0203	CbGbCtD
Dihydroergotamine—ABCB1—Docetaxel—prostate cancer	0.00582	0.0202	CbGbCtD
Dihydroergotamine—CYP3A4—Prednisone—prostate cancer	0.00502	0.0174	CbGbCtD
Dihydroergotamine—ABCB1—Doxorubicin—prostate cancer	0.00434	0.0151	CbGbCtD
Dihydroergotamine—CYP3A4—Etoposide—prostate cancer	0.00381	0.0132	CbGbCtD
Dihydroergotamine—CYP3A4—Docetaxel—prostate cancer	0.00349	0.0121	CbGbCtD
Dihydroergotamine—CYP3A4—Doxorubicin—prostate cancer	0.0026	0.00903	CbGbCtD
Dihydroergotamine—Ergoloid mesylate—CYP3A4—prostate cancer	0.000349	0.566	CrCbGaD
Dihydroergotamine—Ergotamine—CYP3A4—prostate cancer	0.000136	0.221	CrCbGaD
Dihydroergotamine—Bromocriptine—CYP3A4—prostate cancer	0.000131	0.213	CrCbGaD
Dihydroergotamine—Diarrhoea—Estradiol—prostate cancer	5.75e-05	0.000402	CcSEcCtD
Dihydroergotamine—Hypertension—Docetaxel—prostate cancer	5.72e-05	0.0004	CcSEcCtD
Dihydroergotamine—Bronchitis—Doxorubicin—prostate cancer	5.71e-05	0.0004	CcSEcCtD
Dihydroergotamine—Palpitations—Capecitabine—prostate cancer	5.67e-05	0.000397	CcSEcCtD
Dihydroergotamine—Decreased appetite—Etoposide—prostate cancer	5.66e-05	0.000396	CcSEcCtD
Dihydroergotamine—Arthralgia—Docetaxel—prostate cancer	5.64e-05	0.000395	CcSEcCtD
Dihydroergotamine—Myalgia—Docetaxel—prostate cancer	5.64e-05	0.000395	CcSEcCtD
Dihydroergotamine—Asthenia—Mitoxantrone—prostate cancer	5.62e-05	0.000393	CcSEcCtD
Dihydroergotamine—Fatigue—Etoposide—prostate cancer	5.61e-05	0.000393	CcSEcCtD
Dihydroergotamine—Pain—Etoposide—prostate cancer	5.57e-05	0.000389	CcSEcCtD
Dihydroergotamine—Conjunctivitis—Epirubicin—prostate cancer	5.56e-05	0.000389	CcSEcCtD
Dihydroergotamine—Dizziness—Estradiol—prostate cancer	5.56e-05	0.000389	CcSEcCtD
Dihydroergotamine—Hypertension—Capecitabine—prostate cancer	5.54e-05	0.000388	CcSEcCtD
Dihydroergotamine—Dry mouth—Docetaxel—prostate cancer	5.52e-05	0.000386	CcSEcCtD
Dihydroergotamine—Upper respiratory tract infection—Doxorubicin—prostate cancer	5.52e-05	0.000386	CcSEcCtD
Dihydroergotamine—Pollakiuria—Doxorubicin—prostate cancer	5.49e-05	0.000384	CcSEcCtD
Dihydroergotamine—Myalgia—Capecitabine—prostate cancer	5.47e-05	0.000382	CcSEcCtD
Dihydroergotamine—Arthralgia—Capecitabine—prostate cancer	5.47e-05	0.000382	CcSEcCtD
Dihydroergotamine—Confusional state—Docetaxel—prostate cancer	5.46e-05	0.000382	CcSEcCtD
Dihydroergotamine—Anxiety—Capecitabine—prostate cancer	5.45e-05	0.000381	CcSEcCtD
Dihydroergotamine—Oedema—Docetaxel—prostate cancer	5.41e-05	0.000379	CcSEcCtD
Dihydroergotamine—Discomfort—Capecitabine—prostate cancer	5.4e-05	0.000378	CcSEcCtD
Dihydroergotamine—Epistaxis—Epirubicin—prostate cancer	5.4e-05	0.000378	CcSEcCtD
Dihydroergotamine—Sinusitis—Epirubicin—prostate cancer	5.37e-05	0.000376	CcSEcCtD
Dihydroergotamine—Feeling abnormal—Etoposide—prostate cancer	5.37e-05	0.000375	CcSEcCtD
Dihydroergotamine—Diarrhoea—Mitoxantrone—prostate cancer	5.36e-05	0.000375	CcSEcCtD
Dihydroergotamine—Dry mouth—Capecitabine—prostate cancer	5.35e-05	0.000374	CcSEcCtD
Dihydroergotamine—Vomiting—Estradiol—prostate cancer	5.34e-05	0.000374	CcSEcCtD
Dihydroergotamine—Gastrointestinal pain—Etoposide—prostate cancer	5.32e-05	0.000372	CcSEcCtD
Dihydroergotamine—Shock—Docetaxel—prostate cancer	5.32e-05	0.000372	CcSEcCtD
Dihydroergotamine—Ill-defined disorder—Prednisone—prostate cancer	5.31e-05	0.000371	CcSEcCtD
Dihydroergotamine—Rash—Estradiol—prostate cancer	5.3e-05	0.000371	CcSEcCtD
Dihydroergotamine—Dermatitis—Estradiol—prostate cancer	5.29e-05	0.00037	CcSEcCtD
Dihydroergotamine—Confusional state—Capecitabine—prostate cancer	5.28e-05	0.00037	CcSEcCtD
Dihydroergotamine—Tachycardia—Docetaxel—prostate cancer	5.28e-05	0.000369	CcSEcCtD
Dihydroergotamine—Headache—Estradiol—prostate cancer	5.26e-05	0.000368	CcSEcCtD
Dihydroergotamine—Agitation—Prednisone—prostate cancer	5.25e-05	0.000368	CcSEcCtD
Dihydroergotamine—Oedema—Capecitabine—prostate cancer	5.24e-05	0.000366	CcSEcCtD
Dihydroergotamine—Urticaria—Etoposide—prostate cancer	5.17e-05	0.000362	CcSEcCtD
Dihydroergotamine—Anorexia—Docetaxel—prostate cancer	5.16e-05	0.000361	CcSEcCtD
Dihydroergotamine—Malaise—Prednisone—prostate cancer	5.16e-05	0.000361	CcSEcCtD
Dihydroergotamine—Shock—Capecitabine—prostate cancer	5.15e-05	0.000361	CcSEcCtD
Dihydroergotamine—Rhinitis—Epirubicin—prostate cancer	5.15e-05	0.00036	CcSEcCtD
Dihydroergotamine—Body temperature increased—Etoposide—prostate cancer	5.15e-05	0.00036	CcSEcCtD
Dihydroergotamine—Abdominal pain—Etoposide—prostate cancer	5.15e-05	0.00036	CcSEcCtD
Dihydroergotamine—Conjunctivitis—Doxorubicin—prostate cancer	5.15e-05	0.00036	CcSEcCtD
Dihydroergotamine—Vertigo—Prednisone—prostate cancer	5.14e-05	0.000359	CcSEcCtD
Dihydroergotamine—Tachycardia—Capecitabine—prostate cancer	5.11e-05	0.000358	CcSEcCtD
Dihydroergotamine—Hypoaesthesia—Epirubicin—prostate cancer	5.11e-05	0.000358	CcSEcCtD
Dihydroergotamine—Pharyngitis—Epirubicin—prostate cancer	5.1e-05	0.000357	CcSEcCtD
Dihydroergotamine—Hyperhidrosis—Capecitabine—prostate cancer	5.06e-05	0.000354	CcSEcCtD
Dihydroergotamine—Hypotension—Docetaxel—prostate cancer	5.06e-05	0.000354	CcSEcCtD
Dihydroergotamine—Epistaxis—Doxorubicin—prostate cancer	4.99e-05	0.000349	CcSEcCtD
Dihydroergotamine—Anorexia—Capecitabine—prostate cancer	4.99e-05	0.000349	CcSEcCtD
Dihydroergotamine—Nausea—Estradiol—prostate cancer	4.99e-05	0.000349	CcSEcCtD
Dihydroergotamine—Vomiting—Mitoxantrone—prostate cancer	4.98e-05	0.000348	CcSEcCtD
Dihydroergotamine—Sinusitis—Doxorubicin—prostate cancer	4.97e-05	0.000348	CcSEcCtD
Dihydroergotamine—Visual impairment—Epirubicin—prostate cancer	4.95e-05	0.000346	CcSEcCtD
Dihydroergotamine—Hypertension—Prednisone—prostate cancer	4.94e-05	0.000345	CcSEcCtD
Dihydroergotamine—Rash—Mitoxantrone—prostate cancer	4.94e-05	0.000345	CcSEcCtD
Dihydroergotamine—Dermatitis—Mitoxantrone—prostate cancer	4.93e-05	0.000345	CcSEcCtD
Dihydroergotamine—Musculoskeletal discomfort—Docetaxel—prostate cancer	4.93e-05	0.000345	CcSEcCtD
Dihydroergotamine—Headache—Mitoxantrone—prostate cancer	4.9e-05	0.000343	CcSEcCtD
Dihydroergotamine—Hypotension—Capecitabine—prostate cancer	4.9e-05	0.000342	CcSEcCtD
Dihydroergotamine—Insomnia—Docetaxel—prostate cancer	4.89e-05	0.000342	CcSEcCtD
Dihydroergotamine—Arthralgia—Prednisone—prostate cancer	4.87e-05	0.000341	CcSEcCtD
Dihydroergotamine—Myalgia—Prednisone—prostate cancer	4.87e-05	0.000341	CcSEcCtD
Dihydroergotamine—Paraesthesia—Docetaxel—prostate cancer	4.86e-05	0.00034	CcSEcCtD
Dihydroergotamine—Anxiety—Prednisone—prostate cancer	4.85e-05	0.000339	CcSEcCtD
Dihydroergotamine—Dyspnoea—Docetaxel—prostate cancer	4.82e-05	0.000337	CcSEcCtD
Dihydroergotamine—Somnolence—Docetaxel—prostate cancer	4.81e-05	0.000337	CcSEcCtD
Dihydroergotamine—Discomfort—Prednisone—prostate cancer	4.81e-05	0.000336	CcSEcCtD
Dihydroergotamine—Hypersensitivity—Etoposide—prostate cancer	4.8e-05	0.000336	CcSEcCtD
Dihydroergotamine—Tinnitus—Epirubicin—prostate cancer	4.79e-05	0.000335	CcSEcCtD
Dihydroergotamine—Musculoskeletal discomfort—Capecitabine—prostate cancer	4.77e-05	0.000334	CcSEcCtD
Dihydroergotamine—Flushing—Epirubicin—prostate cancer	4.77e-05	0.000334	CcSEcCtD
Dihydroergotamine—Rhinitis—Doxorubicin—prostate cancer	4.77e-05	0.000333	CcSEcCtD
Dihydroergotamine—Dyspepsia—Docetaxel—prostate cancer	4.76e-05	0.000333	CcSEcCtD
Dihydroergotamine—Insomnia—Capecitabine—prostate cancer	4.74e-05	0.000331	CcSEcCtD
Dihydroergotamine—Hypoaesthesia—Doxorubicin—prostate cancer	4.73e-05	0.000331	CcSEcCtD
Dihydroergotamine—Pharyngitis—Doxorubicin—prostate cancer	4.72e-05	0.00033	CcSEcCtD
Dihydroergotamine—Paraesthesia—Capecitabine—prostate cancer	4.7e-05	0.000329	CcSEcCtD
Dihydroergotamine—Decreased appetite—Docetaxel—prostate cancer	4.7e-05	0.000329	CcSEcCtD
Dihydroergotamine—Asthenia—Etoposide—prostate cancer	4.67e-05	0.000327	CcSEcCtD
Dihydroergotamine—Dyspnoea—Capecitabine—prostate cancer	4.67e-05	0.000327	CcSEcCtD
Dihydroergotamine—Oedema—Prednisone—prostate cancer	4.67e-05	0.000326	CcSEcCtD
Dihydroergotamine—Fatigue—Docetaxel—prostate cancer	4.67e-05	0.000326	CcSEcCtD
Dihydroergotamine—Nausea—Mitoxantrone—prostate cancer	4.65e-05	0.000325	CcSEcCtD
Dihydroergotamine—Pain—Docetaxel—prostate cancer	4.63e-05	0.000324	CcSEcCtD
Dihydroergotamine—Dyspepsia—Capecitabine—prostate cancer	4.61e-05	0.000323	CcSEcCtD
Dihydroergotamine—Chills—Epirubicin—prostate cancer	4.61e-05	0.000322	CcSEcCtD
Dihydroergotamine—Pruritus—Etoposide—prostate cancer	4.61e-05	0.000322	CcSEcCtD
Dihydroergotamine—Shock—Prednisone—prostate cancer	4.59e-05	0.000321	CcSEcCtD
Dihydroergotamine—Visual impairment—Doxorubicin—prostate cancer	4.58e-05	0.00032	CcSEcCtD
Dihydroergotamine—Tachycardia—Prednisone—prostate cancer	4.55e-05	0.000319	CcSEcCtD
Dihydroergotamine—Decreased appetite—Capecitabine—prostate cancer	4.55e-05	0.000319	CcSEcCtD
Dihydroergotamine—Fatigue—Capecitabine—prostate cancer	4.52e-05	0.000316	CcSEcCtD
Dihydroergotamine—Hyperhidrosis—Prednisone—prostate cancer	4.51e-05	0.000316	CcSEcCtD
Dihydroergotamine—Pain—Capecitabine—prostate cancer	4.48e-05	0.000313	CcSEcCtD
Dihydroergotamine—Feeling abnormal—Docetaxel—prostate cancer	4.46e-05	0.000312	CcSEcCtD
Dihydroergotamine—Diarrhoea—Etoposide—prostate cancer	4.46e-05	0.000312	CcSEcCtD
Dihydroergotamine—Anorexia—Prednisone—prostate cancer	4.45e-05	0.000311	CcSEcCtD
Dihydroergotamine—Tinnitus—Doxorubicin—prostate cancer	4.43e-05	0.00031	CcSEcCtD
Dihydroergotamine—Gastrointestinal pain—Docetaxel—prostate cancer	4.42e-05	0.00031	CcSEcCtD
Dihydroergotamine—Flushing—Doxorubicin—prostate cancer	4.41e-05	0.000309	CcSEcCtD
Dihydroergotamine—Tension—Epirubicin—prostate cancer	4.39e-05	0.000307	CcSEcCtD
Dihydroergotamine—Nervousness—Epirubicin—prostate cancer	4.34e-05	0.000304	CcSEcCtD
Dihydroergotamine—Feeling abnormal—Capecitabine—prostate cancer	4.32e-05	0.000302	CcSEcCtD
Dihydroergotamine—Dizziness—Etoposide—prostate cancer	4.31e-05	0.000301	CcSEcCtD
Dihydroergotamine—Muscle spasms—Epirubicin—prostate cancer	4.3e-05	0.000301	CcSEcCtD
Dihydroergotamine—Gastrointestinal pain—Capecitabine—prostate cancer	4.28e-05	0.0003	CcSEcCtD
Dihydroergotamine—Abdominal pain—Docetaxel—prostate cancer	4.28e-05	0.000299	CcSEcCtD
Dihydroergotamine—Body temperature increased—Docetaxel—prostate cancer	4.28e-05	0.000299	CcSEcCtD
Dihydroergotamine—Chills—Doxorubicin—prostate cancer	4.27e-05	0.000298	CcSEcCtD
Dihydroergotamine—Musculoskeletal discomfort—Prednisone—prostate cancer	4.25e-05	0.000297	CcSEcCtD
Dihydroergotamine—Insomnia—Prednisone—prostate cancer	4.22e-05	0.000295	CcSEcCtD
Dihydroergotamine—Paraesthesia—Prednisone—prostate cancer	4.19e-05	0.000293	CcSEcCtD
Dihydroergotamine—Urticaria—Capecitabine—prostate cancer	4.16e-05	0.000291	CcSEcCtD
Dihydroergotamine—Ill-defined disorder—Epirubicin—prostate cancer	4.15e-05	0.00029	CcSEcCtD
Dihydroergotamine—Abdominal pain—Capecitabine—prostate cancer	4.14e-05	0.00029	CcSEcCtD
Dihydroergotamine—Body temperature increased—Capecitabine—prostate cancer	4.14e-05	0.00029	CcSEcCtD
Dihydroergotamine—Vomiting—Etoposide—prostate cancer	4.14e-05	0.00029	CcSEcCtD
Dihydroergotamine—Agitation—Epirubicin—prostate cancer	4.11e-05	0.000287	CcSEcCtD
Dihydroergotamine—Dyspepsia—Prednisone—prostate cancer	4.11e-05	0.000287	CcSEcCtD
Dihydroergotamine—Rash—Etoposide—prostate cancer	4.11e-05	0.000287	CcSEcCtD
Dihydroergotamine—Dermatitis—Etoposide—prostate cancer	4.1e-05	0.000287	CcSEcCtD
Dihydroergotamine—Headache—Etoposide—prostate cancer	4.08e-05	0.000285	CcSEcCtD
Dihydroergotamine—Tension—Doxorubicin—prostate cancer	4.06e-05	0.000284	CcSEcCtD
Dihydroergotamine—Decreased appetite—Prednisone—prostate cancer	4.06e-05	0.000284	CcSEcCtD
Dihydroergotamine—Malaise—Epirubicin—prostate cancer	4.03e-05	0.000282	CcSEcCtD
Dihydroergotamine—Fatigue—Prednisone—prostate cancer	4.02e-05	0.000281	CcSEcCtD
Dihydroergotamine—Nervousness—Doxorubicin—prostate cancer	4.02e-05	0.000281	CcSEcCtD
Dihydroergotamine—Vertigo—Epirubicin—prostate cancer	4.02e-05	0.000281	CcSEcCtD
Dihydroergotamine—Hypersensitivity—Docetaxel—prostate cancer	3.99e-05	0.000279	CcSEcCtD
Dihydroergotamine—Muscle spasms—Doxorubicin—prostate cancer	3.98e-05	0.000278	CcSEcCtD
Dihydroergotamine—Palpitations—Epirubicin—prostate cancer	3.95e-05	0.000276	CcSEcCtD
Dihydroergotamine—Asthenia—Docetaxel—prostate cancer	3.88e-05	0.000272	CcSEcCtD
Dihydroergotamine—Nausea—Etoposide—prostate cancer	3.87e-05	0.000271	CcSEcCtD
Dihydroergotamine—Hypertension—Epirubicin—prostate cancer	3.86e-05	0.00027	CcSEcCtD
Dihydroergotamine—Hypersensitivity—Capecitabine—prostate cancer	3.86e-05	0.00027	CcSEcCtD
Dihydroergotamine—Feeling abnormal—Prednisone—prostate cancer	3.85e-05	0.000269	CcSEcCtD
Dihydroergotamine—Ill-defined disorder—Doxorubicin—prostate cancer	3.84e-05	0.000269	CcSEcCtD
Dihydroergotamine—Pruritus—Docetaxel—prostate cancer	3.83e-05	0.000268	CcSEcCtD
Dihydroergotamine—Gastrointestinal pain—Prednisone—prostate cancer	3.82e-05	0.000267	CcSEcCtD
Dihydroergotamine—Arthralgia—Epirubicin—prostate cancer	3.81e-05	0.000266	CcSEcCtD
Dihydroergotamine—Myalgia—Epirubicin—prostate cancer	3.81e-05	0.000266	CcSEcCtD
Dihydroergotamine—Agitation—Doxorubicin—prostate cancer	3.8e-05	0.000266	CcSEcCtD
Dihydroergotamine—Anxiety—Epirubicin—prostate cancer	3.79e-05	0.000265	CcSEcCtD
Dihydroergotamine—Discomfort—Epirubicin—prostate cancer	3.76e-05	0.000263	CcSEcCtD
Dihydroergotamine—Asthenia—Capecitabine—prostate cancer	3.76e-05	0.000263	CcSEcCtD
Dihydroergotamine—Malaise—Doxorubicin—prostate cancer	3.73e-05	0.000261	CcSEcCtD
Dihydroergotamine—Dry mouth—Epirubicin—prostate cancer	3.72e-05	0.00026	CcSEcCtD
Dihydroergotamine—Vertigo—Doxorubicin—prostate cancer	3.72e-05	0.00026	CcSEcCtD
Dihydroergotamine—Urticaria—Prednisone—prostate cancer	3.71e-05	0.000259	CcSEcCtD
Dihydroergotamine—Pruritus—Capecitabine—prostate cancer	3.71e-05	0.000259	CcSEcCtD
Dihydroergotamine—Diarrhoea—Docetaxel—prostate cancer	3.7e-05	0.000259	CcSEcCtD
Dihydroergotamine—Abdominal pain—Prednisone—prostate cancer	3.69e-05	0.000258	CcSEcCtD
Dihydroergotamine—Body temperature increased—Prednisone—prostate cancer	3.69e-05	0.000258	CcSEcCtD
Dihydroergotamine—Confusional state—Epirubicin—prostate cancer	3.68e-05	0.000257	CcSEcCtD
Dihydroergotamine—Palpitations—Doxorubicin—prostate cancer	3.66e-05	0.000256	CcSEcCtD
Dihydroergotamine—Oedema—Epirubicin—prostate cancer	3.65e-05	0.000255	CcSEcCtD
Dihydroergotamine—Shock—Epirubicin—prostate cancer	3.59e-05	0.000251	CcSEcCtD
Dihydroergotamine—Diarrhoea—Capecitabine—prostate cancer	3.58e-05	0.000251	CcSEcCtD
Dihydroergotamine—Dizziness—Docetaxel—prostate cancer	3.58e-05	0.00025	CcSEcCtD
Dihydroergotamine—Hypertension—Doxorubicin—prostate cancer	3.57e-05	0.00025	CcSEcCtD
Dihydroergotamine—Tachycardia—Epirubicin—prostate cancer	3.56e-05	0.000249	CcSEcCtD
Dihydroergotamine—Hyperhidrosis—Epirubicin—prostate cancer	3.53e-05	0.000247	CcSEcCtD
Dihydroergotamine—Myalgia—Doxorubicin—prostate cancer	3.52e-05	0.000246	CcSEcCtD
Dihydroergotamine—Arthralgia—Doxorubicin—prostate cancer	3.52e-05	0.000246	CcSEcCtD
Dihydroergotamine—Anxiety—Doxorubicin—prostate cancer	3.51e-05	0.000246	CcSEcCtD
Dihydroergotamine—Discomfort—Doxorubicin—prostate cancer	3.48e-05	0.000243	CcSEcCtD
Dihydroergotamine—Anorexia—Epirubicin—prostate cancer	3.48e-05	0.000243	CcSEcCtD
Dihydroergotamine—Dizziness—Capecitabine—prostate cancer	3.46e-05	0.000242	CcSEcCtD
Dihydroergotamine—Dry mouth—Doxorubicin—prostate cancer	3.45e-05	0.000241	CcSEcCtD
Dihydroergotamine—Vomiting—Docetaxel—prostate cancer	3.44e-05	0.000241	CcSEcCtD
Dihydroergotamine—Hypersensitivity—Prednisone—prostate cancer	3.44e-05	0.000241	CcSEcCtD
Dihydroergotamine—Rash—Docetaxel—prostate cancer	3.41e-05	0.000239	CcSEcCtD
Dihydroergotamine—Hypotension—Epirubicin—prostate cancer	3.41e-05	0.000239	CcSEcCtD
Dihydroergotamine—Dermatitis—Docetaxel—prostate cancer	3.41e-05	0.000238	CcSEcCtD
Dihydroergotamine—Confusional state—Doxorubicin—prostate cancer	3.41e-05	0.000238	CcSEcCtD
Dihydroergotamine—Headache—Docetaxel—prostate cancer	3.39e-05	0.000237	CcSEcCtD
Dihydroergotamine—Oedema—Doxorubicin—prostate cancer	3.38e-05	0.000236	CcSEcCtD
Dihydroergotamine—Asthenia—Prednisone—prostate cancer	3.35e-05	0.000234	CcSEcCtD
Dihydroergotamine—Vomiting—Capecitabine—prostate cancer	3.33e-05	0.000233	CcSEcCtD
Dihydroergotamine—Musculoskeletal discomfort—Epirubicin—prostate cancer	3.33e-05	0.000233	CcSEcCtD
Dihydroergotamine—Shock—Doxorubicin—prostate cancer	3.32e-05	0.000232	CcSEcCtD
Dihydroergotamine—Rash—Capecitabine—prostate cancer	3.3e-05	0.000231	CcSEcCtD
Dihydroergotamine—Pruritus—Prednisone—prostate cancer	3.3e-05	0.000231	CcSEcCtD
Dihydroergotamine—Insomnia—Epirubicin—prostate cancer	3.3e-05	0.000231	CcSEcCtD
Dihydroergotamine—Dermatitis—Capecitabine—prostate cancer	3.3e-05	0.000231	CcSEcCtD
Dihydroergotamine—Tachycardia—Doxorubicin—prostate cancer	3.3e-05	0.000231	CcSEcCtD
Dihydroergotamine—Headache—Capecitabine—prostate cancer	3.28e-05	0.00023	CcSEcCtD
Dihydroergotamine—Paraesthesia—Epirubicin—prostate cancer	3.28e-05	0.000229	CcSEcCtD
Dihydroergotamine—Hyperhidrosis—Doxorubicin—prostate cancer	3.26e-05	0.000228	CcSEcCtD
Dihydroergotamine—Dyspnoea—Epirubicin—prostate cancer	3.25e-05	0.000228	CcSEcCtD
Dihydroergotamine—Somnolence—Epirubicin—prostate cancer	3.24e-05	0.000227	CcSEcCtD
Dihydroergotamine—Anorexia—Doxorubicin—prostate cancer	3.22e-05	0.000225	CcSEcCtD
Dihydroergotamine—Nausea—Docetaxel—prostate cancer	3.21e-05	0.000225	CcSEcCtD
Dihydroergotamine—Dyspepsia—Epirubicin—prostate cancer	3.21e-05	0.000225	CcSEcCtD
Dihydroergotamine—Diarrhoea—Prednisone—prostate cancer	3.19e-05	0.000223	CcSEcCtD
Dihydroergotamine—Decreased appetite—Epirubicin—prostate cancer	3.17e-05	0.000222	CcSEcCtD
Dihydroergotamine—Hypotension—Doxorubicin—prostate cancer	3.16e-05	0.000221	CcSEcCtD
Dihydroergotamine—Fatigue—Epirubicin—prostate cancer	3.15e-05	0.00022	CcSEcCtD
Dihydroergotamine—Pain—Epirubicin—prostate cancer	3.12e-05	0.000218	CcSEcCtD
Dihydroergotamine—Nausea—Capecitabine—prostate cancer	3.11e-05	0.000218	CcSEcCtD
Dihydroergotamine—Dizziness—Prednisone—prostate cancer	3.09e-05	0.000216	CcSEcCtD
Dihydroergotamine—Musculoskeletal discomfort—Doxorubicin—prostate cancer	3.08e-05	0.000215	CcSEcCtD
Dihydroergotamine—Insomnia—Doxorubicin—prostate cancer	3.05e-05	0.000214	CcSEcCtD
Dihydroergotamine—Paraesthesia—Doxorubicin—prostate cancer	3.03e-05	0.000212	CcSEcCtD
Dihydroergotamine—Dyspnoea—Doxorubicin—prostate cancer	3.01e-05	0.000211	CcSEcCtD
Dihydroergotamine—Feeling abnormal—Epirubicin—prostate cancer	3.01e-05	0.00021	CcSEcCtD
Dihydroergotamine—Somnolence—Doxorubicin—prostate cancer	3e-05	0.00021	CcSEcCtD
Dihydroergotamine—Gastrointestinal pain—Epirubicin—prostate cancer	2.98e-05	0.000209	CcSEcCtD
Dihydroergotamine—Dyspepsia—Doxorubicin—prostate cancer	2.97e-05	0.000208	CcSEcCtD
Dihydroergotamine—Vomiting—Prednisone—prostate cancer	2.97e-05	0.000208	CcSEcCtD
Dihydroergotamine—Rash—Prednisone—prostate cancer	2.94e-05	0.000206	CcSEcCtD
Dihydroergotamine—Dermatitis—Prednisone—prostate cancer	2.94e-05	0.000206	CcSEcCtD
Dihydroergotamine—Decreased appetite—Doxorubicin—prostate cancer	2.94e-05	0.000205	CcSEcCtD
Dihydroergotamine—Headache—Prednisone—prostate cancer	2.92e-05	0.000205	CcSEcCtD
Dihydroergotamine—Fatigue—Doxorubicin—prostate cancer	2.91e-05	0.000204	CcSEcCtD
Dihydroergotamine—Urticaria—Epirubicin—prostate cancer	2.9e-05	0.000203	CcSEcCtD
Dihydroergotamine—Pain—Doxorubicin—prostate cancer	2.89e-05	0.000202	CcSEcCtD
Dihydroergotamine—Abdominal pain—Epirubicin—prostate cancer	2.89e-05	0.000202	CcSEcCtD
Dihydroergotamine—Body temperature increased—Epirubicin—prostate cancer	2.89e-05	0.000202	CcSEcCtD
Dihydroergotamine—Feeling abnormal—Doxorubicin—prostate cancer	2.78e-05	0.000195	CcSEcCtD
Dihydroergotamine—Nausea—Prednisone—prostate cancer	2.77e-05	0.000194	CcSEcCtD
Dihydroergotamine—Gastrointestinal pain—Doxorubicin—prostate cancer	2.76e-05	0.000193	CcSEcCtD
Dihydroergotamine—Hypersensitivity—Epirubicin—prostate cancer	2.69e-05	0.000188	CcSEcCtD
Dihydroergotamine—Urticaria—Doxorubicin—prostate cancer	2.68e-05	0.000188	CcSEcCtD
Dihydroergotamine—Body temperature increased—Doxorubicin—prostate cancer	2.67e-05	0.000187	CcSEcCtD
Dihydroergotamine—Abdominal pain—Doxorubicin—prostate cancer	2.67e-05	0.000187	CcSEcCtD
Dihydroergotamine—Asthenia—Epirubicin—prostate cancer	2.62e-05	0.000183	CcSEcCtD
Dihydroergotamine—Pruritus—Epirubicin—prostate cancer	2.58e-05	0.000181	CcSEcCtD
Dihydroergotamine—Diarrhoea—Epirubicin—prostate cancer	2.5e-05	0.000175	CcSEcCtD
Dihydroergotamine—Hypersensitivity—Doxorubicin—prostate cancer	2.49e-05	0.000174	CcSEcCtD
Dihydroergotamine—Asthenia—Doxorubicin—prostate cancer	2.42e-05	0.000169	CcSEcCtD
Dihydroergotamine—Dizziness—Epirubicin—prostate cancer	2.41e-05	0.000169	CcSEcCtD
Dihydroergotamine—Pruritus—Doxorubicin—prostate cancer	2.39e-05	0.000167	CcSEcCtD
Dihydroergotamine—Vomiting—Epirubicin—prostate cancer	2.32e-05	0.000162	CcSEcCtD
Dihydroergotamine—Diarrhoea—Doxorubicin—prostate cancer	2.31e-05	0.000162	CcSEcCtD
Dihydroergotamine—Rash—Epirubicin—prostate cancer	2.3e-05	0.000161	CcSEcCtD
Dihydroergotamine—Dermatitis—Epirubicin—prostate cancer	2.3e-05	0.000161	CcSEcCtD
Dihydroergotamine—Headache—Epirubicin—prostate cancer	2.29e-05	0.00016	CcSEcCtD
Dihydroergotamine—Dizziness—Doxorubicin—prostate cancer	2.23e-05	0.000156	CcSEcCtD
Dihydroergotamine—Nausea—Epirubicin—prostate cancer	2.17e-05	0.000152	CcSEcCtD
Dihydroergotamine—Vomiting—Doxorubicin—prostate cancer	2.15e-05	0.00015	CcSEcCtD
Dihydroergotamine—Rash—Doxorubicin—prostate cancer	2.13e-05	0.000149	CcSEcCtD
Dihydroergotamine—Dermatitis—Doxorubicin—prostate cancer	2.13e-05	0.000149	CcSEcCtD
Dihydroergotamine—Headache—Doxorubicin—prostate cancer	2.12e-05	0.000148	CcSEcCtD
Dihydroergotamine—Nausea—Doxorubicin—prostate cancer	2.01e-05	0.00014	CcSEcCtD
Dihydroergotamine—HTR1B—Signaling Pathways—CDKN1B—prostate cancer	3.29e-06	6.64e-05	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—IL2—prostate cancer	3.29e-06	6.64e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—PIK3CG—prostate cancer	3.28e-06	6.62e-05	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling by GPCR—IL6—prostate cancer	3.28e-06	6.61e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—ITPR1—prostate cancer	3.27e-06	6.6e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—IL2—prostate cancer	3.27e-06	6.59e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—GPCR downstream signaling—AKT1—prostate cancer	3.26e-06	6.57e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—TERT—prostate cancer	3.26e-06	6.57e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—CREBBP—prostate cancer	3.24e-06	6.53e-05	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—CCND1—prostate cancer	3.23e-06	6.52e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—CASP3—prostate cancer	3.23e-06	6.51e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—IL2—prostate cancer	3.22e-06	6.5e-05	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—CCND1—prostate cancer	3.21e-06	6.47e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling by GPCR—IL6—prostate cancer	3.21e-06	6.47e-05	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—CTNNB1—prostate cancer	3.2e-06	6.46e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—IGF1—prostate cancer	3.2e-06	6.44e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—NCOA3—prostate cancer	3.19e-06	6.44e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling by GPCR—EGFR—prostate cancer	3.18e-06	6.41e-05	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—CTNNB1—prostate cancer	3.18e-06	6.41e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—CXCL8—prostate cancer	3.17e-06	6.39e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—CCND1—prostate cancer	3.14e-06	6.34e-05	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—MMP9—prostate cancer	3.14e-06	6.33e-05	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—CDKN1A—prostate cancer	3.13e-06	6.31e-05	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—PTEN—prostate cancer	3.12e-06	6.3e-05	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—MMP9—prostate cancer	3.12e-06	6.28e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—HIF1A—prostate cancer	3.11e-06	6.28e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—CTNNB1—prostate cancer	3.11e-06	6.28e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—INS—prostate cancer	3.1e-06	6.26e-05	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—CDKN1A—prostate cancer	3.1e-06	6.26e-05	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—PTEN—prostate cancer	3.1e-06	6.25e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—CDKN1B—prostate cancer	3.09e-06	6.24e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—TYMS—prostate cancer	3.09e-06	6.23e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—MAP2K1—prostate cancer	3.09e-06	6.23e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Hemostasis—AKT1—prostate cancer	3.09e-06	6.23e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—PIK3CD—prostate cancer	3.07e-06	6.19e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—GPCR downstream signaling—AKT1—prostate cancer	3.06e-06	6.17e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—GSTM1—prostate cancer	3.05e-06	6.16e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—MMP9—prostate cancer	3.05e-06	6.15e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—HPGDS—prostate cancer	3.05e-06	6.14e-05	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling by GPCR—AKT1—prostate cancer	3.05e-06	6.14e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—CREBBP—prostate cancer	3.04e-06	6.13e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—CDKN1A—prostate cancer	3.04e-06	6.13e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—LEP—prostate cancer	3.04e-06	6.13e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—GPCR downstream signaling—PIK3CA—prostate cancer	3.04e-06	6.13e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—SERPINE1—prostate cancer	3.03e-06	6.12e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—PTEN—prostate cancer	3.03e-06	6.12e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—CASP3—prostate cancer	3.03e-06	6.12e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—IL2—prostate cancer	3.03e-06	6.11e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—CYP2C19—prostate cancer	3.03e-06	6.11e-05	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling by GPCR—AKT1—prostate cancer	3.02e-06	6.09e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling by GPCR—IL6—prostate cancer	3.01e-06	6.08e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—CAV1—prostate cancer	3.01e-06	6.07e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling by GPCR—KRAS—prostate cancer	3e-06	6.06e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—LPL—prostate cancer	3e-06	6.05e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—KDR—prostate cancer	2.98e-06	6e-05	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—EP300—prostate cancer	2.98e-06	6e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling by GPCR—AKT1—prostate cancer	2.96e-06	5.97e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—GSTT1—prostate cancer	2.95e-06	5.96e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—ACHE—prostate cancer	2.95e-06	5.96e-05	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—EP300—prostate cancer	2.95e-06	5.96e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—CCND1—prostate cancer	2.95e-06	5.95e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—FGF2—prostate cancer	2.94e-06	5.92e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—CTNNB1—prostate cancer	2.92e-06	5.9e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—CYP2A6—prostate cancer	2.92e-06	5.89e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—ESR1—prostate cancer	2.9e-06	5.85e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—NOS3—prostate cancer	2.9e-06	5.84e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—CYP1A1—prostate cancer	2.9e-06	5.84e-05	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—SRC—prostate cancer	2.89e-06	5.84e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—EP300—prostate cancer	2.89e-06	5.83e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—PIK3CD—prostate cancer	2.88e-06	5.82e-05	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—SRC—prostate cancer	2.87e-06	5.79e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—ERCC2—prostate cancer	2.87e-06	5.79e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—MMP9—prostate cancer	2.87e-06	5.78e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—CDKN1A—prostate cancer	2.86e-06	5.76e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—PTEN—prostate cancer	2.85e-06	5.75e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—AKR1C3—prostate cancer	2.84e-06	5.73e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—BAD—prostate cancer	2.83e-06	5.71e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—PRKACB—prostate cancer	2.83e-06	5.7e-05	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—VEGFA—prostate cancer	2.82e-06	5.69e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—JAK2—prostate cancer	2.82e-06	5.68e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—SRC—prostate cancer	2.81e-06	5.67e-05	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—VEGFA—prostate cancer	2.8e-06	5.64e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—CYP17A1—prostate cancer	2.8e-06	5.64e-05	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—STAT3—prostate cancer	2.79e-06	5.63e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling by GPCR—AKT1—prostate cancer	2.78e-06	5.61e-05	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—STAT3—prostate cancer	2.77e-06	5.59e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling by GPCR—PIK3CA—prostate cancer	2.76e-06	5.56e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—MDM2—prostate cancer	2.75e-06	5.54e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—APC—prostate cancer	2.74e-06	5.53e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—PIK3CG—prostate cancer	2.74e-06	5.53e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—VEGFA—prostate cancer	2.74e-06	5.53e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—NOS3—prostate cancer	2.72e-06	5.49e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—EP300—prostate cancer	2.72e-06	5.48e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—STAT3—prostate cancer	2.71e-06	5.47e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—IRS1—prostate cancer	2.71e-06	5.47e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—EGF—prostate cancer	2.71e-06	5.47e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—ERBB2—prostate cancer	2.71e-06	5.46e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—MTHFR—prostate cancer	2.7e-06	5.44e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—PIK3CB—prostate cancer	2.67e-06	5.39e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—NCOA2—prostate cancer	2.67e-06	5.37e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—PPARA—prostate cancer	2.65e-06	5.34e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—SRC—prostate cancer	2.64e-06	5.33e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—GSK3B—prostate cancer	2.63e-06	5.31e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—INS—prostate cancer	2.6e-06	5.24e-05	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—MYC—prostate cancer	2.59e-06	5.23e-05	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—TGFB1—prostate cancer	2.59e-06	5.22e-05	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—MYC—prostate cancer	2.57e-06	5.19e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—VEGFA—prostate cancer	2.57e-06	5.19e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—CXCL8—prostate cancer	2.57e-06	5.18e-05	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—TGFB1—prostate cancer	2.57e-06	5.18e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—STAT3—prostate cancer	2.55e-06	5.14e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—CREBBP—prostate cancer	2.54e-06	5.13e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—SLC5A5—prostate cancer	2.54e-06	5.13e-05	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—EGFR—prostate cancer	2.54e-06	5.12e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—MYC—prostate cancer	2.52e-06	5.08e-05	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—EGFR—prostate cancer	2.52e-06	5.08e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—TGFB1—prostate cancer	2.51e-06	5.07e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—PIK3CB—prostate cancer	2.51e-06	5.07e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—IGF1—prostate cancer	2.51e-06	5.06e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—CDKN1B—prostate cancer	2.51e-06	5.06e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—EGFR—prostate cancer	2.5e-06	5.04e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—PTGS2—prostate cancer	2.49e-06	5.02e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—CAV1—prostate cancer	2.49e-06	5.02e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—CYP2E1—prostate cancer	2.48e-06	5.01e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—GPCR downstream signaling—AKT1—prostate cancer	2.48e-06	5.01e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—EGFR—prostate cancer	2.47e-06	4.97e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—CASP3—prostate cancer	2.46e-06	4.96e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—IL2—prostate cancer	2.46e-06	4.95e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—NQO1—prostate cancer	2.46e-06	4.95e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling by GPCR—IL6—prostate cancer	2.44e-06	4.93e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—MAP2K1—prostate cancer	2.43e-06	4.89e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—TH—prostate cancer	2.42e-06	4.88e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—PIK3CD—prostate cancer	2.41e-06	4.86e-05	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—KRAS—prostate cancer	2.4e-06	4.83e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—CCND1—prostate cancer	2.39e-06	4.83e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—GPCR downstream signaling—PIK3CA—prostate cancer	2.39e-06	4.82e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—SERPINE1—prostate cancer	2.38e-06	4.81e-05	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—KRAS—prostate cancer	2.38e-06	4.8e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—CTNNB1—prostate cancer	2.37e-06	4.78e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—MYC—prostate cancer	2.37e-06	4.78e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—TGFB1—prostate cancer	2.36e-06	4.76e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—KRAS—prostate cancer	2.36e-06	4.76e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—CYP1B1—prostate cancer	2.35e-06	4.75e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—KRAS—prostate cancer	2.33e-06	4.7e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—MMP9—prostate cancer	2.32e-06	4.69e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—EGFR—prostate cancer	2.32e-06	4.67e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—CDKN1A—prostate cancer	2.32e-06	4.67e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—PTEN—prostate cancer	2.31e-06	4.66e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—FGF2—prostate cancer	2.31e-06	4.66e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—GGT1—prostate cancer	2.28e-06	4.6e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—NOS3—prostate cancer	2.28e-06	4.59e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—PIK3CG—prostate cancer	2.27e-06	4.57e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling by GPCR—AKT1—prostate cancer	2.25e-06	4.55e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—NCOA1—prostate cancer	2.25e-06	4.53e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—CYP19A1—prostate cancer	2.21e-06	4.46e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—JAK2—prostate cancer	2.21e-06	4.46e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—EP300—prostate cancer	2.2e-06	4.44e-05	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—PIK3CA—prostate cancer	2.2e-06	4.44e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—KRAS—prostate cancer	2.19e-06	4.41e-05	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—PIK3CA—prostate cancer	2.19e-06	4.41e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—PTEN—prostate cancer	2.17e-06	4.38e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—PIK3CA—prostate cancer	2.17e-06	4.37e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—MDM2—prostate cancer	2.16e-06	4.36e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—INS—prostate cancer	2.15e-06	4.33e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—SRC—prostate cancer	2.14e-06	4.32e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—PIK3CA—prostate cancer	2.14e-06	4.32e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—RXRA—prostate cancer	2.14e-06	4.31e-05	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—TP53—prostate cancer	2.13e-06	4.3e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—ERBB2—prostate cancer	2.13e-06	4.29e-05	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—TP53—prostate cancer	2.11e-06	4.26e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—CREBBP—prostate cancer	2.1e-06	4.24e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—PIK3CB—prostate cancer	2.1e-06	4.24e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—VEGFA—prostate cancer	2.09e-06	4.21e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—EP300—prostate cancer	2.07e-06	4.18e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—TP53—prostate cancer	2.07e-06	4.17e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—STAT3—prostate cancer	2.07e-06	4.17e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—COMT—prostate cancer	2.06e-06	4.15e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—GSTP1—prostate cancer	2.05e-06	4.13e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—CXCL8—prostate cancer	2.02e-06	4.07e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—ITPR1—prostate cancer	2.02e-06	4.06e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—PIK3CA—prostate cancer	2.01e-06	4.05e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—PIK3CD—prostate cancer	1.99e-06	4.02e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—CDKN1B—prostate cancer	1.97e-06	3.98e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—GPCR downstream signaling—AKT1—prostate cancer	1.95e-06	3.93e-05	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—IL6—prostate cancer	1.95e-06	3.93e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—TP53—prostate cancer	1.94e-06	3.92e-05	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—IL6—prostate cancer	1.94e-06	3.9e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—CASP3—prostate cancer	1.93e-06	3.9e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—IL2—prostate cancer	1.93e-06	3.89e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—IL6—prostate cancer	1.92e-06	3.87e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—MYC—prostate cancer	1.92e-06	3.87e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—TGFB1—prostate cancer	1.92e-06	3.86e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—TYMS—prostate cancer	1.9e-06	3.84e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—IL6—prostate cancer	1.89e-06	3.82e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—NOS3—prostate cancer	1.88e-06	3.8e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—GSTM1—prostate cancer	1.88e-06	3.8e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—CCND1—prostate cancer	1.88e-06	3.79e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—EGFR—prostate cancer	1.88e-06	3.79e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—CTNNB1—prostate cancer	1.86e-06	3.76e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—LPL—prostate cancer	1.85e-06	3.73e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—MMP9—prostate cancer	1.83e-06	3.68e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—CDKN1A—prostate cancer	1.82e-06	3.67e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—PTEN—prostate cancer	1.82e-06	3.66e-05	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—AKT1—prostate cancer	1.8e-06	3.63e-05	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—AKT1—prostate cancer	1.79e-06	3.6e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—CYP1A1—prostate cancer	1.78e-06	3.6e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—IL6—prostate cancer	1.78e-06	3.59e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—KRAS—prostate cancer	1.77e-06	3.58e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—AKT1—prostate cancer	1.77e-06	3.57e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—ERCC2—prostate cancer	1.77e-06	3.57e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—AKT1—prostate cancer	1.75e-06	3.53e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—PIK3CB—prostate cancer	1.74e-06	3.51e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—EP300—prostate cancer	1.73e-06	3.49e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—PTGS2—prostate cancer	1.72e-06	3.47e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—SRC—prostate cancer	1.68e-06	3.4e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—MTHFR—prostate cancer	1.66e-06	3.35e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—AKT1—prostate cancer	1.64e-06	3.31e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—VEGFA—prostate cancer	1.64e-06	3.31e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—PPARA—prostate cancer	1.63e-06	3.29e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—PIK3CA—prostate cancer	1.63e-06	3.29e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—STAT3—prostate cancer	1.62e-06	3.28e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—TP53—prostate cancer	1.58e-06	3.18e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—CAV1—prostate cancer	1.53e-06	3.09e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—PIK3CA—prostate cancer	1.53e-06	3.09e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—MYC—prostate cancer	1.51e-06	3.04e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—TGFB1—prostate cancer	1.51e-06	3.04e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—PTEN—prostate cancer	1.5e-06	3.03e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—EGFR—prostate cancer	1.48e-06	2.98e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—IL6—prostate cancer	1.44e-06	2.91e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—EP300—prostate cancer	1.43e-06	2.89e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—PIK3CG—prostate cancer	1.4e-06	2.82e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—KRAS—prostate cancer	1.39e-06	2.81e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—AKT1—prostate cancer	1.33e-06	2.69e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—INS—prostate cancer	1.32e-06	2.67e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—CREBBP—prostate cancer	1.3e-06	2.61e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—PIK3CA—prostate cancer	1.28e-06	2.58e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—AKT1—prostate cancer	1.25e-06	2.52e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—TP53—prostate cancer	1.24e-06	2.5e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—PIK3CD—prostate cancer	1.23e-06	2.48e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—NOS3—prostate cancer	1.16e-06	2.34e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—IL6—prostate cancer	1.13e-06	2.29e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—PIK3CB—prostate cancer	1.07e-06	2.16e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—PTGS2—prostate cancer	1.06e-06	2.14e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—PIK3CA—prostate cancer	1.06e-06	2.14e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—AKT1—prostate cancer	1.05e-06	2.11e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—PTEN—prostate cancer	9.25e-07	1.87e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—EP300—prostate cancer	8.82e-07	1.78e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—AKT1—prostate cancer	8.66e-07	1.75e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—PIK3CA—prostate cancer	6.53e-07	1.32e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—AKT1—prostate cancer	5.33e-07	1.08e-05	CbGpPWpGaD
